miRview® mets(2), a Second Generation Version of their miRview® mets Test Features an Expanded Panel of 42 Tumor Origin, and Improved Classifiers
PHILADELPHIA, PA and REHOVOT, ISRAEL–(Marketwire – December 13, 2010) – Rosetta Genomics, Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics announces today the commercial availability of miRview® mets² (“miRview mets two”), a microRNA-based test that identifies the primary origin of tumors of uncertain or unknown origin. The new test, which builds on the technology and know-how of miRview® mets, offers physicians and patients a larger panel of 42 tumors that can be identified, an increase from the 25 tumors that can be identified in the previous version of the test. In addition, the new assay offers identification of sarcomas, lymphomas and other non-epithelial malignancies as well as more histologic subtypes. Furthermore, the test features improved classifiers which incorporate clinical, biological and molecular knowledge.